An estimated 38,000 Americans are diagnosed with HIV annually. An important tool in the effort to end the ongoing epidemic is an injectable form of pre-exposure prophylaxis (PrEP), the first option to prevent HIV that does not involve taking a daily pill. The injectable form of the drug received FDA approval in late 2021 and has begun to hit the market. This is Part 2 of our conversation (Recorded May 16, 2022) with a panel of experts specializing in the HIV treatment and prevention. They discuss the benefits and what people at risk for HIV should know, challenges of implementation among providers and more. 

The panel includes: 

David Rosenthal, DO, PhD, medical director for the Center for Young Adult, Adolescent and Pediatric HIV.

Demetre Daskalakis, MD, director of the Division of HIV/AIDS Prevention (DHAP) for the Centers for Disease Control and Prevention (CDC)

Charles Gonzalez, MD, medical director for the New York State Department of Health's AIDS Institute

More from the experts

Dr. Rosenthal talks strengthening HIV prevention with PrEP and expanding the four key strategies to end AIDS by 2030.